Use of immune serum globulin (human) to reduce mortality in newly imported rhesus monkeys (Macaca mulatta)

Immune serum globulin (human) (ISGH) was administered intramuscularly to approximately 5,600 rhesus monkeys weighing between 1.5 and 3.6 kg. The animals were housed at three separate facilities under differing quarantine conditions. ISGH recipients were grossly healthier, suffered less morbidity and fewer developed antibodies against measles (rubeola) virus. Mortality among ISGH-treated animals was only 20-57% of that in the control animals. No adverse effects were seen from the injection of ISGH into rhesus monkeys, and residual antibodies from the injected material could not be detected 18 and 47 days postinoculation.